Literature DB >> 6300737

Motion sickness: a modulatory role for the central cholinergic nervous system.

R L Kohl, J L Homick.   

Abstract

The present review has extended the general theory of motion sickness proposed by Wood and Graybiel [135, 136] by identifying specific neurophysiological mechanisms that are involved in motion sickness and by interpreting the actions of both scopolamine and amphetamine as effective anti-motion sickness drugs within this neurophysiological context. The neurochemical and neurophysiological effects of scopolamine have been reviewed in relationship to central cholinergic pathways. Cholinergic pathways have been associated with both the perception and expression of normal and excessive levels of motion stimuli. New approaches to the problem of the prevention of motion sickness have been considered. Efferent nicotinic innervation at the primary sensory hair cells and the medial vestibular nucleus were identified as sites where modulation by cholinergic drugs might exert a beneficial influence. However, it was generally conceded that the complexity of the cholinergic system and the interaction of scopolamine with that system left open the possibility that pharmacological doses of drugs specific to the cholinergic system might exert significant modulatory influences at alternative sites, as well.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6300737     DOI: 10.1016/0149-7634(83)90008-8

Source DB:  PubMed          Journal:  Neurosci Biobehav Rev        ISSN: 0149-7634            Impact factor:   8.989


  6 in total

1.  Gastric myoelectrical and autonomic cardiac reactivity to laboratory stressors.

Authors:  P J Gianaros; K S Quigley; J T Mordkoff; R M Stern
Journal:  Psychophysiology       Date:  2001-07       Impact factor: 4.016

2.  Relationship between temporal changes in cardiac parasympathetic activity and motion sickness severity.

Authors:  Peter J Gianaros; Karen S Quigley; Eric R Muth; Max E Levine; Raymond C Vasko; Robert M Stern
Journal:  Psychophysiology       Date:  2003-01       Impact factor: 4.016

3.  The effects of transdermal scopolamine and four dose levels of oral scopolamine (0.15, 0.3, 0.6, and 1.2 mg) upon psychological performance.

Authors:  A C Parrott
Journal:  Psychopharmacology (Berl)       Date:  1986       Impact factor: 4.530

4.  Body volume changes during simulated microgravity: auditory changes, segmental fluid redistribution, and regional hemodynamics.

Authors:  L D Montgomery; A J Parmet; C R Booher
Journal:  Ann Biomed Eng       Date:  1993 Jul-Aug       Impact factor: 3.934

5.  Promethazine, scopolamine and cinnarizine: comparative time course of psychological performance effects.

Authors:  A C Parrott; K Wesnes
Journal:  Psychopharmacology (Berl)       Date:  1987       Impact factor: 4.530

6.  Central and peripheral effects of arecoline in patients with autonomic failure.

Authors:  R J Polinsky; R T Brown; M T Curras; S M Baser; C E Baucom; D R Hooper; A M Marini
Journal:  J Neurol Neurosurg Psychiatry       Date:  1991-09       Impact factor: 10.154

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.